SAR425899
Sponsors
Sanofi
Conditions
Non-alcoholic SteatohepatitisType 2 Diabetes Mellitus
Phase 1
Multiple Ascending Dose Study in Healthy Male Subjects and Overweight to Obese Male and Female Type 2 Diabetes Mellitus (T2DM) Patients
CompletedNCT02411825
Start: 2015-03-31End: 2016-01-31Updated: 2018-06-15
A Clinical Study to Investigate if SAR425899 Binds to the Liver and Pancreas in Overweight to Obese Type 2 Diabetes Mellitus Patients
CompletedNCT03350191
Start: 2017-12-20End: 2018-06-07Updated: 2022-04-25
A Clinical Study to Investigate the Effect of SAR425899 on Energy Expenditure in Obese Subjects
CompletedNCT03376802
Start: 2018-04-18End: 2018-12-27Updated: 2022-04-25
A Study on Safety and Tolerability of SAR425899 in Overweight to Obese Subjects and Type 2 Diabetes Mellitus Patients Not Requiring Anti-Diabetic Pharmacotherapy With an Optional 6-month Safety Extension Period
CompletedNCT03414736
Start: 2018-01-19End: 2018-10-05Updated: 2022-04-25
Phase 2
A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus
CompletedNCT02973321
Start: 2016-12-02End: 2017-12-27Updated: 2022-03-24
Assessment of the Safety and Effect of SAR425899 Versus Placebo for the Treatment of Non-alcoholic Fatty Liver Disease
WithdrawnNCT03437720
Start: 2019-05-23End: 2021-08-25Updated: 2022-04-13